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CONTINUING EDUCATION
Comparing the 2013 ACC/AHA & 2014 NLA Dyslipidemia Guidelines 
and their Impact on Clinical Decision Making
by Alexander Forbes, Pharm.D. Candidate, Midwestern University College of Pharmacy-Glendale Class of 2015, 
Kevin Grimes, Pharm.D.Candidate Midwestern University College of Pharmacy-Glendale Class of 2015, Jocelyn 
York, Pharm.D. Candidate Midwestern University College of Pharmacy-Glendale Class of 2015, and Laura Tsu, 
Pharm.D., BCPS, Assistant Professor, Pharmacy Practice, Midwestern University College of Pharmacy-Glendale
Goal:
This home-study CPE activity has been developed to 
educate pharmacists on the similarities and differences 
between the 2014 NLA Recommendations for Dyslipid-
emia Management and the 2013 ACC/AHA Guidelines for 
Treatment of Blood Cholesterol.
At the conclusion of this CPE activity, successful partici-
pants should be able to:
Objectives for Pharmacists: 
1. Identify the major differences in treatment recommenda-
tions for dyslipidemia between the 2013 ACC/AHA Guidelines 
and the new 2014 NLA Recommendations for dyslipidemia. 
2. List the classifications of lipoprotein lipid levels in adults.
3. Accurately identify targets for intervention in the treatment 
of dyslipidemia.
4. Assess a patient’s ASCVD risk and the treatment goals based 
on risk category.
5. Discuss lifestyle and drug therapies recommended to reduce 
morbidity and mortality in patients with dyslipidemia.
6. Apply NLA guidelines to formulate and evaluate initial or 
existing therapy to specific patient cases.
Objectives for Technicians: 
1. Identify the major differences in treatment recommenda-
tions for dyslipidemia between the 2013 ACC/AHA Guidelines 
and the new 2014 NLA Recommendations for Dyslipidemia.
2. List the classifications of lipoprotein lipid levels in adults.
3. Learn how the pharmacist can use NCA guidelines and the 
ASCVD risk to assess and evaluate patients. 
This presents a significant public health challenge 
for the medical community. Over the past decade 
and a half, dyslipidemia management has been 
the focus of numerous organizations, all aiming to 
decrease the morbidity and mortality associated 
with poor lipid control. And progress has been 
made: the relative rate of death related to heart 
disease has decreased by approximately 31% 
from 2000-2010.3 However, there is much more 
that still needs to be accomplished in the fight 
against dyslipidemia. 
       Many organizations and agencies have com-
piled recommendations for the management of 
dyslipidemia. Though commonalities exist, there 
are stark differences between these varied guide-
lines. This continuing education article strives to 
compare and contrast previous recommendations 
with the recent National Lipid Association (NLA) 
recommendations, as to provide a clear and com-
prehensive understanding of the varied approach 
to management of dyslipidemia.
Background
       Cholesterol, triglycerides and lipoproteins 
comprise the major lipids in the human body and 
when transported in the blood stream, are known 
as lipoproteins. There are three major serum 
lipoproteins: LDL, high-density lipoprotein (HDL) 
and very low-density lipoprotein (VLDL) which are 
carried in the blood as triglycerides (TG). Dyslipid-
emia is defined as a disorder of these key lipopro-
teins. This disease state may commonly be char-
acterized by an elevation in total cholesterol, an 
elevation in LDL, an elevation in TG, or a decrease 
in HDL concentrations in the blood. Progression 
of dyslipidemia is facilitated through a number of 
mechanisms. As LDL levels increase in the blood, 
the particles become lodged in the artery wall, 
causing atherosclerotic lesions. Once in the artery 
wall, LDL becomes oxidized, triggering an immune 
response via macrophages. Macrophages, in an 
attempt to engulf and clear the LDL particles, 
Introduction
      Dyslipidemia, or high cholesterol, is a major risk 
factor for the development of heart disease, the leading 
cause of death in the United States (US).1 The Centers for 
Disease Control and Prevention estimates that 71 million 
Americans, roughly one-third of the entire population, 
have high low-density lipoprotein (LDL) cholesterol.2 This 
staggering number emphasizes the need for proper man-
agement of high cholesterol in the US and around the 
world. Sadly, it’s estimated that only one-third of the 71 
million Americans with high LDL are well-controlled. 
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unintentionally cause an acceleration of LDL oxida-
tion. Further involvement of the immune system 
leads to an inflammatory response and formation 
of atherosclerotic plaques. Eventually, after years of 
repetitive vessel damage, formed plaques and choles-
terol deposits begin to occlude blood vessels leading 
to atherosclerotic cardiovascular disease (ASCVD). 
ASCVD encompasses all cardiovascular disease that 
is attributable to atherosclerotic plaque formation 
including, but not limited to, myocardial infarction, 
angina, and peripheral artery disease. It is this ASCVD 
that is of most concern when discussing management 
of dyslipidemia and prevention of cardiovascular 
events.4
Timeline of Dyslipidemia Management
       The past decade and a half has seen the update 
and release of three distinct dyslipidemia guide-
lines. The first, produced by the National Cholesterol 
Education Program (NCEP), were known as the Adult 
Treatment Panel (ATP) guidelines. ATP I was released 
in 1988 followed by ATP II in 1993. The most recent 
and applicable update to these recommendations 
was released in 2002 and was known as ATP III. The 
ATP III recommendations focused on intensive LDL 
lowering strategies mediated by goal-directed ther-
apy as well as primary prevention in patients with 
multiple risk factors.4 For many years, the ATP III 
guidelines were the standard of care in clinical prac-
tice until the 2013 release of the American College of 
Cardiology/American Heart Association (ACC/AHA) 
dyslipidemia recommendations. The ACC/AHA 2013 
guidelines demonstrated a shift in approach to lipid 
management. While primary prevention remained a 
focus, goal-directed therapy did not. Instead, inten-
sive statin therapy became the center of the ACC/
AHA recommendations, with little regard to other 
aspects of clinical management. Because the ACC/
AHA guidelines are still relatively new, their imple-
mentation and understanding in clinical practice is 
still developing.
2013 ACC/AHA Guidelines Overview
       The ACC/AHA expert panel took a different ap-
proach in regards to lipid management when com-
pared to the ATP III guidelines. They determined that, 
based on available evidence, there was no significant 
morbidity or mortality benefit of titrating pharma-
cotherapy to target a specific LDL goal.5 In addition, 
the percentage of ASCVD risk reduction that one goal 
level offered in comparison to another, for exam-
ple lowering LDL-C to optimal (<100 mg/dL) versus 
lowering it to near optimal (100-129 mg/dL), was 
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Table 1 - Statin Benefit Groups* 
Individuals with clinical ASCVD 
Individuals with primary elevation of LDL-C ≥190 mg/dL 
Individuals age 40-75 with Diabetes Mellitus with LDL-C 70-189 mg/dL 
Individuals without diabetes or clinical ASCVD who are 40-75 years of age with LDL-c 70-189 mg/dL and who 
have an estimated 10-year ASCVD risk 7.5% or higher 
*Adapted from reference 7 
 
Table 2 - High- Moderate- and Low- Intensity Statin Therapy&* 
High-Intensity Statin Therapy 
 
Moderate-Intensity Statin Therapy 
 
Low-Intensity Statin Therapy 
Daily dose lowers LDL-C on 
average, by ≥ 50% 
Daily dose lowers LDL-C on 
average, by 30-50% 
Daily dose lowers LDL-C on 
average, by ≤ 30% 
Atorvastatin 40-80 mg 
Rosuvastatin 20-40 mg 
Atorvastatin 10-20 mg 
Rosuvastatin 5-10 mg 
Simvastatin 20-40 mg 
Pravastatin 40-80 mg 
Lovastatin 40 mg 
Fluvastatin 40 mg bid 
Fluvastatin XL 80 mg^ 
Pitavastatin 2-4 mg^ 
Simvastatin 10 mg^ 
Pravastatin 10–20 mg 
Lovastatin 20 mg 
Fluvastatin 20–40 mg^ 
Pitavastatin 1 mg^ 
*Individual response may vary between each patient in clinical 
practice 
^FDA approved but have not been evaluated by RCT’s 
 
&Adapted from reference 7 
  
Figure 1 – Adapated from reference 7  
 
never quantified in studies. Therefore, the idea that 
the lowest level is best was not supported in the ACC/
AHA guidelines. They did, however, conclude that 
evidence did support a significant morbidity and mor-
tality benefit with moderate to high intensity statin 
use. Based on this data, the panel concluded that the 
sole focus of treatment should be on intensive sta-
tin therapy. Upon review of current clinical trial and 
epidemiologic data, the ACC/AHA expert panel stated 
that there were four specific “statin benefit” groups 
(Table 1). Additionally, the panel advocated the use of 
the Pooled-Cohort ASCVD Risk Calculator to further 
identify high risk patients.6 There are a number of 
online versions of this Pooled-Cohort calculator avail-
able to aid pharmacists in risk stratifying patients. 
The ACC/AHA then classified the intensity of certain 
statins for use in the previously discussed statin bene-
fit groups (Table 2). The intensity of a statin was defined 
by the percent reduction in LDL-C, as deduced from 
systematic reviews of RCT’s. Finally, based upon an 
individual’s ASCVD risk and statin benefit group, their 
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need for a moderate or high intensity statin could be 
determined. The ACC/AHA created a final algorithm to 
guide statin therapy (Figure 1). 
2014 NLA Recommendations Overview
       The National Lipid Association (NLA) is an ac-
credited, multidisciplinary organization consisting of 
physicians, pharmacists, and other healthcare profes-
sionals and researchers whose focus is on enhancing 
lipid management in clinical practice. The NLA Expert 
Panel’s Recommendations for Patient-Centered Man-
agement of Dyslipidemia utilized current randomized 
controlled data along with epidemiological and genetic 
studies to determine beneficial interventions on clinical 
ASCVD events.7 The panel focused on a patient-cen-
tered approach to lipid management and emphasized 
the importance of clinical judgment based on individ-
ual factors. The NLA made six major evidence-based 
conclusions which guided the formation of the recom-
mendations:
1. An elevated level of cholesterol carried by circulating 
apolipoprotein (apo) B-containing lipoproteins (non-
HDL-C and LDL-C, termed atherogenic cholesterol) is a 
root cause of atherosclerosis, the key underlying pro-
cess contributing to most clinical ASCVD events. 
       In light of the recent compelling evidence found in 
randomized-controlled trials (RCTs), epidemiological 
and genetic studies, the NLA recommendations shift 
away from the previous focus on LDL cholesterol as the 
sole contributor to ASCVD risk. The expert panel con-
cluded that non-HDL-C, in conjunction with LDL-C, are 
the primary targets of therapy, with non-HDL-C being 
a preferred primary target over LDL-C. This is because 
non-HDL-C is thought to be a better predictor of ASCVD 
morbidity and mortality as it includes the cholesterol 
carried by all lipid particles that are potentially athero-
genic. Therefore, non-HDL presumably provides a more 
accurate picture of an individual patient’s risk. The 
NLA suggests that a reduction in levels of atherogenic 
cholesterol will proportionally reduce the risk of ASCVD 
events in patients with dyslipidemia.  
       The NLA provides an optional secondary target for 
treatment in certain patients. ApoB is a lipoprotein that 
is found on the surface of LDL-C particles. Each LDL-C 
particle contains one molecule of apoB; therefore, the 
concentration of apoB in the bloodstream is directly 
proportional to the number of circulating atherogenic 
particles.  Unfortunately, apoB has not been con-
sistently shown to be a superior measurement in 
comparison to non-HDL-C and levels of apoB can be 
altered by current statin use. These limiting factors 
relegate the use of apoB to an optional target for 
treatment. It is important to note that the phar-
macological effect that statins have on cholesterol 
levels is that it most often lowers cholesterol con-
centrations to a greater extent than it does apoB 
levels.  The apoB remaining after treatment goals 
for non-HDL-C and LDL-C (see Table 3) are reached 
is recognized as a contributor to any remaining ASC-
VD risk.  Therefore, apoB levels may then be target-
ed to further reduce this risk after individuals reach 
their goal levels for non-HDL-C and LDL-C.
2. Reducing elevated levels of atherogenic cho-
lesterol will lower ASCVD risk in proportion to the 
extent that atherogenic cholesterol is reduced. This 
benefit is presumed to result from atherogenic 
cholesterol lowering through multiple modalities, 
including lifestyle and drug therapies. 
       The second major conclusion from the NLA 
asserts that the amount that cholesterol is reduced 
in the blood proportionally reduces ASCVD risk. A 
meta-analysis evaluating the relationship between 
non-HDL-C lowering and coronary heart disease risk 
reduction compiled data from 14moderate to high 
intensity statin dose placebo and active control tri-
als. Researchers found that a 1% reduction in non-
HDL-C resulted in a 4.5-year coronary heart disease 
(CHD) relative risk reduction of 1%.8 It would stand 
to reason that a greater reduction in atherogenic 
cholesterol would result in an overall decreased risk 
of cardiovascular events. This reduction is mediat-
ed by cholesterol-targeting medications, namely 
statins, diet and exercise.
3. The intensity of risk-reduction therapy should 
generally be adjusted to the patient’s absolute risk 
for an ASCVD event.
       The NLA based the recommendation for in-
creased intensity of statin therapy in proportion to 
an individual’s risk on current evidence and clinical 
consensus. The conclusion is thus: as an individual’s 
ASCVD risk increases, the need for greater reduc-
tion in atherogenic cholesterol is also required to 
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prevent a cardiovascular event. This intensive de-
crease is mediated by the use of appropriate statin 
therapy (Table 2). It stands to reason that if a greater 
reduction of cholesterol is necessary, then a higher 
intensity statin should be more efficacious than a 
lower intensity statin. The Cholesterol Treatment Tri-
alists’ Collaboration undertook meta-analyses of indi-
vidual trial data examining the efficacy and safety of 
lower versus higher intensity statin doses. Research-
ers found that higher intensity regimens resulted in 
significantly fewer major vascular events [15% RR 
(95% CI 11—18); p<0.0001], revascularization [19% 
RR (95% CI 15—24); p<0.0001] and ischemic stroke 
[16% RR (95% CI 5—26); p=0.005].9 Therefore, the 
NLA’s third major conclusion is supported. 
4. Atherosclerosis is a process that often begins early 
in life and progresses for decades before resulting 
in a clinical ASCVD event. Therefore, both interme-
diate-term and long-term/lifetime risk should be 
considered when assessing the potential benefits and 
hazards of risk-reduction therapies.
       The basis of this major conclusion was founded 
on the fact that there can be significant differences 
between a patient’s short-term risk and their lifetime 
risk. The NLA recommends avoiding a “one-size-fits-
all” approach and instead advocates for a compre-
hensive work-up of each patient and an individual 
treatment plan tailored to their specific short-term 
and lifetime ASCVD risk.
5. For patients in whom lipid-lowering drug therapy 
is indicated, statin treatment is the primary modality 
for reducing ASCVD risk.
       Statin therapy has proven to be the golden stan-
dard in dyslipidemia management. This stems from 
the fact that statins provide the greatest percentage 
LDL-C lowering and therefore, the greatest reduction 
in cardiovascular risk. High intensity statins lower 
LDL-C by an average of 50% from baseline whereas 
moderate intensity statins provide a 30-50% reduc-
tion in LDL-C (Table 2). Alternative lipid-lowering thera-
pies do not provide as substantial a mortality benefit 
as statins and therefore are reserved as last-line 
therapy if a patient is unable or unwilling to continue 
statin therapy.
6. Non-lipid ASCVD risk factors should also be man-
aged appropriately, particularly high blood pressure, 
cigarette smoking and diabetes mellitus.
       ASCVD is multifactorial and involves more than 
dyslipidemia management. Comorbid disease states 
can further contribute to ASCVD risk, such as diabe-
tes, hypertension and coronary artery disease. Addi-
tionally, poor diet and cigarette smoking compound 
CHD risk. Smoking alone is attributed to 30% of all 
CHD deaths in the United States, though this number 
is likely higher.10 Addressing these additional risk fac-
tors in conjunction with proper dyslipidemia manage-
ment can further decrease an individual’s ASCVD risk.
How the Guidelines Differ – Risk Assessment 
       When comparing the ACC/AHA guidelines with 
the NLA recommendations, there are significant 
differences that arise when assessing an individual’s 
cardiovascular risk. While both guidelines similarly 
define clinical evidence of ASCVD, the approach to 
further risk stratification differs. The ACC/AHA utilizes 
the Pooled-Cohort calculator to determine an individ-
ual’s 10-year risk of developing ASCVD. The combina-
tion of clinical ASCVD, age, and the 10-year risk score 
all contribute to the ultimate decision of whether a 
patient receives a moderate or high intensity statin. 
The NLA on the other hand, only recommends us-
ing the Pooled-Cohort calculator as a supplement 
when determining an individual’s treatment strategy. 
Where the ACC/AHA only recommends the use of 
their own calculator for further risk assessment, the 
NLA gives the option of either the ATP III Framingham 
risk calculator, the Framingham long-term (30-year), 
or the ACC/AHA Pooled Cohort Equations calcula-
tor. The NLA acknowledges that scoring calculators 
provide only an estimate of risk for these patients, 
and should be used as a means of more accurately 
reclassifying moderate risk individuals as high risk for 
optimal treatment outcomes.7 The NLA recommends 
consideration of other factors that may influence 
risk categorization to the high risk category for more 
appropriate treatment goals. The presence of meta-
bolic syndrome and other clinical risk indicators that 
warrant the use of the Pooled-Cohort calculator are 
outlined in Table 8. The ACC/AHA on the other hand 
incorporates the risk calculator into assessing risk for 
determining appropriate statin intensity for two of 
the four statin benefit groups: patients with diabe-
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tes type 1 or 2 age 40-75 years, and patients without 
diabetes age 40 to 75 years with a 10-year assessment 
score of ≥ 7.5%.7
       For patients that fall under the high or very-high 
risk categories, the NLA states that quantitative risk 
scoring is not necessary when certain disease states 
are also present. These conditions include diabetes 
mellitus type 1 or 2, chronic kidney disease stage 3B 
or greater, LDL-C ≥190mg/dL (severe hypercholesterol-
emia) and the presence of ASCVD. The NLA argues that 
quantitative risk scoring in these patients often results 
in underestimation of the patients true risk for an ASC-
VD event, and should therefore be avoided to allow for 
a more accurate determination of patient treatment 
options.7 Individuals in the moderate risk category with 
two major risk factors for ASCVD (Table 5) are often risk 
assessed for purpose of evaluating pharmacotherapy 
when these uncertainties still exist despite their risk 
category. The greatest benefit of quantitative risk scor-
ing in moderate risk patients is in determining if justi-
fication exists for initiating pharmacotherapy when it 
may have otherwise been held. So in general, the NLA 
give clinicians the option of performing quantitative 
risk scoring for patients without high risk conditions 
who nonetheless may be at an increased risk of an 
ASCVD event, or for those who have higher risk factors 
warranting further consideration. As emphasized pre-
viously, this approach differs from the ACC/AHA Guide-
lines that utilize quantitative risk scoring as an essential 
part of the ASCVD classification system.
How the Guidelines Differ – Treatment Goals
       While the ACC/AHA guidelines make no direct as-
sessment to which lipid measurement correlates great-
est with ASCVD risk, the NLA expert panel recognizes 
non-HDL as a superior treatment target compared to 
the traditionally measured LDL-C. The expert panel dis-
cusses that non-HDL accounts for more types of cho-
lesterol that contribute to ASCVD, and that non-HDL-C 
better predicts morbidity and mortality over LDL-C.7,11
Target treatment goal recommendations may be the 
most significant difference between the ACC/AHA 
guidelines and the NLA recommendations. The ACC/
AHA guidelines decision to not target treatment goals 
was based upon their review of 23 RCTs for primary 
and secondary prevention (6 for primary and 19 for 
secondary with 2 studies encompassing both pop-
ulations-ASPEN and AURORA) and was two of their 
three critical questions that they addressed while 
formulating their guidelines. The authors did not 
find enough data in these studies to support the 
use of specific treatment goals.7 On the contrary, 
even though the NLA expert panel recognizes in 
their review of available RCTs that treating pa-
tients to specific atherogenic cholesterol goals 
have not been tested as primary efficacy, they view 
treatment goals as a necessary measure in the 
management of dyslipidemia. The NLA states that 
implementing treatment goals enhances patient-cli-
nician communication and assures that appropriate 
risk reduction is occurring. The specific goals for 
each risk group in the NLA guidelines are outlined 
in Table 9.Finally, when comparing the ACC/AHA 
and NLA treatment goals, it is important to analyze 
follow-up recommendations. The ACC/AHA sug-
gest an initial baseline fasting lipid panel at time of 
pharmacotherapy initiation and follow up at 4 to 12 
weeks to access for adherence to pharmacothera-
py and lifestyle modifications. Once a patient has 
been stabilized on pharmacotherapy, the ACC/AHA 
suggests follow-up every 3-12 months thereafter.5 
The NLA guidelines recommend similar time frames 
for follow up with multiple visits over 6 months in 
which target goal levels should be obtained, and 
once goal has been reached follow up should occur 
every 4 to 12 months.7
Pharmacotherapy Management
       The pharmacist’s role in dyslipidemia man-
agement is applicable across multiple patient care 
settings. Whether in an inpatient or outpatient 
setting, a pharmacist’s understanding of basic 
monitoring, adverse events, and laboratory values 
are crucial in providing the best care to individual 
patients. In addition to a fasting lipid panel period-
ically as recommended above, liver function tests 
(LFTs) should be evaluated at baseline, and creatine 
kinase (CK) should be evaluated in select patients. 
However, routine monitoring of these lab values is 
not currently recommended and should only be re-
peated upon a patient’s symptomatic presentation 
or based upon clinical judgment.12
       Pharmacists should monitor for side effects of 
statin therapy, the most common of which are mus-
cle pain and weakness, and gastrointestinal upset 
and headache. More severe adverse effects include 
myopathies and rhabdomyolsis, though the inci-
dence is rare. Pharmacists should evaluate patients 
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muscle pain and recommend laboratory testing of LFTs 
or CK if indicated. In those patients who present with 
muscle pain, symptoms may improve upon switching 
to a different statin. Other strategies suggested by the 
NLA include a modified dosing regimen, such as every 
other day, or lowering the total daily dose. For those 
patients who absolutely cannot tolerate a statin, other 
classes of medications may be considered, either alone 
or in addition to the statin (Table 6). Of note, the NLA 
does not support the use of combination drug therapy 
prior to reaching the maximum tolerated statin dose, 
as evidence justifying this is lacking. 
       Additionally, pharmacists should evaluate the po-
tential for drug-drug interactions. Simvastatin, ator-
vastatin and lovastatin are substrates for CYP3A4 and 
are therefore, the three statins most likely to interact 
with other medications. CYP3A4 inhibitors are of most 
concern, as they can increase serum concentrations 
of these statins and put patients at an increased risk 
of toxicity. However, atorvastatin is less reliant on 
3A4 for metabolism and is involved in fewer clinically 
significant interactions when compared to simvastatin 
and lovastatin. Gemfibrozil inhibits glucuronidation, 
an important elimination pathway for all statins and 
should therefore be avoided with all statin therapy. 
Fenofibrate is an appropriate alternative to gemfibro-
zil and appears to be safe and effective when used 
with statins.13 Finally, patients should be counseled on 
avoidance of grapefruit juice while taking simvastatin 
and lovastatin due to inhibition of 3A4. Consumption 
is not contraindicated in atorvastatin use but intake 
should be limited to less than 1 liter per day. Table 7 
lists other potential drug-drug interactions with select 
statin therapies. 
       Finally, patients with severe hypercholesterolemia 
(LDL-C ≥190 mg/dL) can present significant treatment 
challenges. Even with combination therapy, goal levels 
of atherogenic cholesterol may not be achievable in 
this despite utilizing the most aggressive treatment 
options tolerable.  In an effort to reduce morbidity and 
mortality in patients with severe hypercholesterolemia, 
the NLA recommends a reduction in atherogenic cho-
lesterol by at least 50% instead of the standard goals 
outlined in Table 3.  Although new medication classes 
are being studied that may eventually make the stan-
dard goals in this year’s recommendations achievable 
in patients with excessively elevated cholesterol levels, 
this alternative treatment approach remains the most 
practical option until new agents are proven safe and 
efficacious.
Therapeutic Lifestyle Changes
       The ACC/AHA and the NLA recognize the impor-
tance of lifestyle modifications as a key component 
of dyslipidemia management.  The expert panel 
recommends a 3-month trial of lifestyle therapy 
for patients who fall into the low to moderate risk 
categories prior to drug therapy.  For high and very 
high risk patients, however, drug therapy may be 
initiated at the same time as lifestyle therapy.
       Lifestyle changes should be a focus at every 
visit, with an emphasis on diet, exercise and smok-
ing cessation. Patients with dyslipidemia should 
be educated on how to maintain a balanced diet, 
low in saturated fats and sodium and high in fiber. 
The DASH diet and the AHA’s dietary recommen-
dations are all highly recommended diet plans and 
can aid in both cholesterol and blood pressure 
reduction.14,15 While pharmacists can provide basic 
nutritional education and support, referral to a 
registered dietician is recommended.  Additionally, 
moderate to high intensity exercise ideally targeting 
150 minutes per week (30 minutes per day for 5 
days) is highly encouraged. For those patients who 
are overweight or obese, a weight loss of 5% to 
10% of body weight over 6 months is recommend-
ed.  Smoking cessation should be encouraged at 
each follow-up and referral to patient resources, 
should be provided as needed.  
Conclusion
       Clinical practices in the medical community are 
constantly adapting as new data becomes avail-
able. This is illustrated by the rapidly changing lipid 
recommendations over the past decade and a half. 
A thorough review of the 2013 ACC/AHA guide-
lines in comparison to the newly released 2014 
NLA recommendations reveals both commonali-
ties as well as differences. The release of the NLA 
recommendations saw the resurrection of lipid 
goals while retaining the focus on intensive statin 
therapy. As a pharmacist, it is fundamental to have 
an understanding these current practice guidelines 
and familiarize oneself with the preceding relevant 
recommendations. 
       Pharmacists play a significant role in the man-
agement of patients with dyslipidemia. They are 
some of the most accessible members of the health 
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 Table 3 – NLA Classifications of Cholesterol and 
Triglyceride levels in mg/dL 
Non-HDL-C 
<130 
130-159 
160-189 
190-219 
≥220 
Desirable 
Above desirable 
Borderline high 
High 
Very high 
LDL-C 
<100 
100-129 
130-159 
160-189 
≥190 
Desirable 
Above desirable 
Borderline high 
High 
Very high 
HDL-C 
<40 (men) 
<50 (women) 
Low 
Low 
Triglycerides 
<150  
150-199 
200-499 
≥500 
Normal 
Borderline high 
High 
Very high 
Adapted from reference 8 
 Table 6 - Lipoprotein Metabolism of Other Agents 
Drug class Lipoproteins Effects 
Bile Acid 
Sequestrants 
LDL-C 
Non-HDL-C 
HDL-C 
TG 
↓15-30% 
↓4-16% 
↑3-5% 
↓0-10% 
Nicotinic Acids LDL-C 
Non-HDL-C 
HDL-C 
TG 
↓5-25% 
↓8-23% 
↑15-35% 
↓20-50% 
Fibric Acids LDL-C 
Non-HDL-C 
HDL-C 
TG 
↓5-20% 
↓5-19% 
↑10-20% 
↓20-50% 
Cholesterol 
Absorption Inhibitor 
LDL-C 
Non-HDL-C 
HDL-C 
TG 
↓13-20% 
↓14-19% 
↑3-5% 
↓5-11% 
Long-Chain Omega-3 
Fatty Acids 
LDL-C 
Non-HDL-C 
HDL-C 
TG 
↓6%-↑25% 
↓5-14% 
↑5%-↓7% 
↓19-44% 
Adapted from reference 8 
 Table 7 - Statin Metabolism 
Statin Metabolic 
Pathway 
Potential Interactions 
Lovastatin 
Simvastatin 
Atorvastatin 
3A4 Ketoconazole, itraconazole, 
cyclosporine, erythromycin, 
clarithromycin, ritonavir 
Gemfibrozil 
Rosuvastatin Minimal 2C9 Cyclosporine, gemfibrozil 
Fluvastatin 2C9, 3A4, 2D6 Warfarin, gemfibrozil 
Pitavastatin Minimal 2C9 Gemfibrozil 
Pravastatin None 
significant 
Gemfibrozil 
Adapted from reference 17 
care team and are convenient resources for patients. They have 
the potential to make substantial interventions in patient care, 
involving encouragement of therapeutic lifestyle changes, ad-
verse drug event monitoring, and medication adherence. Given 
that pharmacists work closely alongside medical practitioners, it 
is essential to remain up to date on the current evidence based 
guidelines, as to provide accurate and timely pharmacotherapy 
recommendations.
Table 4 – NLA Risk Assessment 
Major Risk Factors for 
ASCVD 
Evidence of Clinical ASCVD 
Criteria 
High or Very High Risk Patient 
Groups 
 Age 
- Male ≥45 years 
- Female ≥55 years 
 Family history of early CHD 
- Male <55 years of age first 
degree relative 
- Female <65 years of age 
first-degree relative 
 Current cigarette use 
 High blood pressure 
(≥140/≥90 mmHg) or on 
blood pressure medication 
 Low HDL-C 
- Male <40 mg/dL 
- Female <50 mg/dL 
 MI or ACS 
 Coronary or other 
revascularization procedure 
 Ischemic stroke or TIA 
 Atherosclerotic peripheral arterial 
disease 
- Includes ankle/brachial index 
<0.90 
 Other documented atherosclerotic 
   diseases such as: 
- Coronary atherosclerosis 
- Renal atherosclerosis 
- Aortic aneurysm secondary to 
     atherosclerosis 
Quantitative risk scoring is not 
necessary for initial risk assessment 
in patients with the following 
conditions: 
 Diabetes mellitus, Type 1 or 2 
 Chronic kidney disease, stage ≥3B 
 LDL-C ≥190 mg/dL or severe 
hypercholesterolemia phenotype 
 ASCVD 
Adapted from reference 8 
 
Table 5 - Comparison of ACC/AHA and NLA Treatment Goals 
2013 ACC/AHA Guidelines 2014 NLA Recommendations 
1 No recommendation for non-HDL-C vs. LDL-C Recommends monitoring of non-HDL-C over LDL-C 
2  Excludes target lipid goals 
 4 statin benefit groups 
1. Clinical ASCVD 
2. LDL-C ≥190 mg/dL 
3. 40-75 years old with DM (I or II) 
4. Absence of ASCVD or DM, 40-75 years 
old with LDL-C 70-189mg/dL and an 
estimated 10-year ASCVD risk ≥ 7.5% 
 Utilizes treatment lipid goals and pharmacotherapy 
therapy intervention levels 
 Risk Category Target Goal (Non-HDL-C, LDL-C) 
1. Low           (<130, <100) 
2. Moderate  (<130, <100) 
3. High          (<130, <100) 
4. Very High  (<100, <70) 
3 Follow up visit in 4 to 12 weeks to assess 
adherence, then every 3 to 12 months 
Goal levels should be reached by approximately 6 
months, then follow-up every 3-12 months 
Adapted from reference 8 
 
 
Table 8 - Criteria for Clinical Identification of Metabolic Syndrome 
Measure Criteria 
1. Elevated waist circumference   ≥40 inches in men 
  ≥35 inches in women 
2. Elevated triglycerides*   ≥150 mg/dL 
3. Reduced HDL-C   <40 mg/dL in men 
  <50 mg/dL in women 
4. Elevated blood pressure*   Systolic ≥130 and/or diastolic ≥85 mm Hg 
5. Elevated fasting glucose*   ≥40 inches in men 
  ≥35 inches in women 
*Drug treatment with a triglyceride-lowering agent, drug treatment of elevated blood 
pressure, and drug treatment of elevated blood glucose are alternative indicators for 
metabolic syndrome 
 Adapted from reference 8 
Table 9 - NLA Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and 
Levels at Which to Consider Drug Therapy 
Risk category  Criteria  Treatment goal  
Non-HDL-C mg/dL  
LDL-C mg/dL  
Apo B mg/dL*  
Consider drug therapy  
Non-HDL-C mg/dL  
LDL-C mg/dL  
Apo B mg/dL*  
Low   Major ASCVD risk factors 
 Consider other risk factors, if known  
<130 
<100 
<90*  
≥190 
≥160  
Moderate   2 major ASCVD risk factors 
 Consider quantitative risk scoring 
 Consider other risk indicators  
<130 
<100 
<90*  
≥160 
≥130  
High   ≥3 major ASCVD risk factors 
 Diabetes mellitus (type 1 or 2) 
- 0-1 other major ASCVD risk factors and 
- No evidence of end organ damage 
 Chronic kidney disease stage 3B or 4 
 LDL-C ≥190 mg/dL (severe 
   hypercholesterolemia) 
 Quantitative risk score reaching the high-
risk threshold  
<130 
<100 
<90*  
≥130 
≥100  
Very High   ASCVD 
 Diabetes mellitus (type 1 or 2) 
- ≥2 other major ASCVD risk factors or 
- Evidence of end organ damage  
<100 
<70 
<80*  
≥100 
≥70  
For patients with ASCVD or diabetes mellitus, consideration should be given to use of moderate or high-intensity 
statin therapy, irrespective of baseline atherogenic cholesterol levels.  
*Apo B is a secondary, optional target of treatment 
Adapted from reference 8 
 
Dyslipidemia
Summer 2015 • ArizonA JournAl of PhArmAcy • 31CONTINUING EDUCATION
References
1. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: 
final data for 2007. Hyattsville, MD: US Department of 
Health and Human Services, CDC, National Center for 
Health Statistics; 2010. National Vital Statistics Report, vol. 
58, no. 19.
2. CDC. Vital signs: prevalence, treatment, and control 
of high levels of low-density lipoprotein cholesterol. 
United States, 1999–2002 and 2005–2008. MMWR. 
2011;60(4):109–14.
3. Go AS, Mozaffarian D, Roger VL et al. Heart disease 
and stroke statistics – 2014 update: a report from the 
American Heart Association. Circulation. 2014 Jan 
21;129(3):e28-e292. 
4. Third report of the expert panel on detection , evalua-
tion, and treatment of high cholesterol in adults (the adult 
treatment panel III). Circulation. 2002.
5. Dipiro JT, Talbert RL, Yee Gc et al. Pharmacotherapy: a 
pathophysiologic approach, 9th edition. New York: Mc-
Graw-Hill Medical. 2008;1:11. 
6. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to re-
duce atherosclerotic cardiovascular risk in adults: a report 
of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. Circulation. 
2014;129(25 Suppl 2):S1-45.
7. Goff DC, Lloyd-Jones DM, Bennett D et al. 2013 ACC/
AHA Guideline on the Assessment of Cardiovascular Risk: 
A Report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines. Circu-
lation. 2014; 129: S49-S73.
8. Jacobson TA, Ito MK, Maki KC et al. National Lipid Asso-
ciation recommendations for patient-centered manage-
ment of dyslipidemia: Part 1 - executive summary. J Clin 
Lipidol. 2014;8(5):473-88.
9. Robinson JG, Wang S, Smith BJ et al. Meta-analysis of 
the relationship between non-high-density lipoprotein 
cholesterol reduction and coronary heart disease risk. J 
Am Coll Cardiol. 2009;53(4):316-22.
10. Baigent C, Blackwell L, Emberson J et al. Cholesterol 
treatment trialists’ (CTT) collaboration: Efficacy and safety 
of more intensive lowering of LDL cholesterol: a meta-an-
aylsis of data from 170,000 participants in 26 randomized 
trials. Lancet. 2010;376:1670-1681.
11. Ockene IS, Miller NH. American Heart Association task 
force on risk reduction: Cigarette smoking, cardiovascular 
disease and stroke. Circulation. 1997;96;3243-7.
12. Liu J, Sempos CT, Donahue RP et al. Non-high-density 
lipoprotein and very-low-density lipoprotein cholesterol 
and their risk predictive values in coronary heart disease. 
Am J Cardiol. 2006;98:1363-1368
13. McKenney JM, Davidson MH, Jacobson TA et al.  Final 
conclusions and recommendations of the National Lipid 
Association Statin Safety Assessment Task Force. Am J 
Cardiol. 2006;97:89C-94C.
14. Davidson MH. Combination therapy for dyslipid-
emia: safety and regulatory considerations. Am J Cardiol. 
2002;69:340-5.
15. US Department of Health and Human Services; Nation-
al Institutes of Health; National Heart, Blood and Lung In-
stitute. Your guide to lowering blood pressure with DASH. 
NIH Publication no. 06-4082, revised April 2006. Available 
at www.nhlbi.nih.gov/files/docs/public/heart/hbp_low.
pdf. Accessed 10/23/14.
16. Lichtenstein AH, Appel LJ, Brands M et al. Diet and 
lifestyle recommendations 2006: A scientific statement 
from the American Heart Association Nutrition Committee. 
Circulation. 2006;114:82-96. 
17. Wiggins BS, Saseen JJ. Pharmacist’s guide to lipid man-
agement. Lanexa, Kasas:ACCP;2014:80-121.
ACPE UAN# 0100-0000-15-043-H04-P; 
0100-0000-15-043-H04-T
To receive CPE credit you must complete the quiz and 
evaluations on page 40 & 42
Looking for Online CEs?
Visit the Arizona Center  
for Professional Education
Your online source for continuing  
pharmacy education 
Visit 
www.azpharmacy.org/AzCPE
Dyslipidemia
